Bank of America Upgrades Fresenius Medical Care (NYSE:FMS) to “Neutral”

Fresenius Medical Care (NYSE:FMS) was upgraded by analysts at Bank of America from an “underperform” rating to a “neutral” rating in a research note issued to investors on Monday, Marketbeat.com reports.

A number of other equities research analysts have also recently commented on FMS. StockNews.com started coverage on shares of Fresenius Medical Care in a report on Thursday, November 28th. They issued a “strong-buy” rating on the stock. Berenberg Bank started coverage on shares of Fresenius Medical Care in a research note on Wednesday, November 6th. They issued a “buy” rating and a $25.60 price objective for the company. Finally, Truist Financial lifted their price objective on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a research note on Monday, October 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $24.30.

Fresenius Medical Care Price Performance

Fresenius Medical Care stock opened at $23.32 on Monday. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. The stock has a market cap of $13.68 billion, a P/E ratio of 19.27, a P/E/G ratio of 1.05 and a beta of 0.94. The company’s 50 day moving average price is $21.07 and its two-hundred day moving average price is $20.31. Fresenius Medical Care has a 52 week low of $17.93 and a 52 week high of $23.45.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Creative Planning grew its position in Fresenius Medical Care by 18.9% in the second quarter. Creative Planning now owns 40,140 shares of the company’s stock worth $766,000 after acquiring an additional 6,373 shares in the last quarter. Wulff Hansen & CO. grew its position in Fresenius Medical Care by 1,809.0% in the second quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock worth $6,556,000 after acquiring an additional 325,439 shares in the last quarter. Marshall Wace LLP lifted its stake in Fresenius Medical Care by 8.5% in the second quarter. Marshall Wace LLP now owns 15,363 shares of the company’s stock worth $293,000 after purchasing an additional 1,207 shares during the last quarter. AQR Capital Management LLC bought a new stake in Fresenius Medical Care in the second quarter worth $197,000. Finally, Moran Wealth Management LLC lifted its stake in Fresenius Medical Care by 47.0% in the third quarter. Moran Wealth Management LLC now owns 233,376 shares of the company’s stock worth $4,971,000 after purchasing an additional 74,621 shares during the last quarter. 8.25% of the stock is currently owned by hedge funds and other institutional investors.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.